FDA OKs additional indication for SPECT agent AdreView

03/24/2013 | AuntMinnie.com (free registration)

The FDA has allowed the use of GE Healthcare's SPECT imaging agent AdreView, also known as iobenguane I-123, in the evaluation of myocardial sympathetic innervation in patients with New York Heart Association class II or III heart failure and left-ventricular ejection fraction at or lower than 35%. The company said the agent has the potential to detect the likelihood that patients' heart failure will advance.

View Full Article in:

AuntMinnie.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ